Evaluation of flunisolide nasal solution in the symptomatic treatment of perennial rhinitis.
The effectiveness of a topical steroid, flunisolide, was evaluated in patients with perennial rhinitis. Thirty-four patients went through a double-blind cross-over study, comparing flunisolide 200 microgram per day with placebo. The symptoms were assessed over two treatment periods each of 4 weeks, with a 2 weeks' washout period in between. There was a statistically significant difference in favour of flunisolide. About half of the patients complained of mild initial irritation from both active drug and placebo.
D000281:Administration, Intranasal; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D005260:Female; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000187:drug effects; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D005446:Fluocinolone Acetonide; C007734:flunisolide